Mount Sinai's $1M XPRIZE Bet: Can the Immune System Be Reset to Fight Aging?

The immune system doesn’t fail dramatically. It slows down across decades in a process so gradual it’s easy to mistake for normal aging — until a $101 million global competition and Mount Sinai’s immunology team start treating it as a reversible condition rather than an inevitable one.

What Happened

Mount Sinai’s Icahn School of Medicine received $1 million as a Milestone 2 Awardee in XPRIZE Healthspan, a seven-year, $101M global competition targeting measurable healthspan extension. The funding supports the NYC-Vita trial, with total resources including testing infrastructure reaching approximately $10 million.

The research team — led by immunologist Dr. Miriam Merad alongside specialists in wearable technology, brain health, and nutrition — is testing a combination of lifestyle modifications and targeted medication to restore immune function to states that participants had years or decades earlier. The goal is not to broadly suppress or boost the immune system, but to help it function the way it did decades earlier.

Why It Matters

The mechanistic target is what makes this study distinctive in a longevity field crowded with supplement protocols and caloric restriction variants. Immune aging — sometimes called immunosenescence — produces a recognizable pattern: fewer naive immune cells capable of responding to new threats, more exhausted and chronically activated cells that generate low-grade inflammation without resolving it. That inflammatory background state is implicated in cardiovascular disease, cognitive decline, and reduced resilience to infection.

Most longevity interventions either ignore the immune system or treat inflammation as a symptom to suppress. The NYC-Vita approach treats the immune system’s functional state as a primary target and measures outcomes against hard endpoints: muscle strength, memory, and immune function in participants aged 50 to 90. The stretch goal is restoring two decades of immune function within one year; the baseline goal is recovering ten years within that window.

What XPRIZE funding adds beyond the money is scientific accountability. The competition requires rigorous measurement against validated biomarkers. Studies that reach milestone funding have cleared peer scrutiny, not just academic enthusiasm.

Researchers working in the aging space, such as Peter Attia, have written extensively about immune function as an underappreciated longevity lever — particularly the distinction between chronic low-grade inflammation (which accelerates disease) and acute immune response (which is protective).

Source: Longevity Technology

Content created with AI assistance and reviewed for accuracy.